-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13, 2022, gene-editing company Eligo Bioscience ("Eligo") and Kantonsspital St.
Eligo, a global leader in microbiome gene editing therapy, is advancing a highly differentiated precision drug pipeline to address unmet medical needs
Through proprietary in vivo gene editing technology, Eligo precisely modifies genes from bacteria that encode disease-driven peptide mimimetics so that these peptides are not immunogenic, thereby eliminating a disease exacerbating factor
Kantonsspital St.
The 21st century is an era of vigorous life sciences, and gene editing has had a profound impact on
Application scenarios for gene editing
From the perspective of technology development, gene editing has experienced the iterative development of zinc finger nucleases (ZFNs), transcriptional activator effector nucleases (TALENs) and CRISPR technology, making the application scenarios more diversified
The medical research of gene editing is still in its preliminary stages, and there are four main problems:
Effectiveness
The way of
Off-target problem
Ethical and security issues
In 2020, the global market size of gene editing services is expected to be 3.
Source:
